Renal Cancer - Results from #1300

Epidemiology of Renal Cell Carcinoma: 2022 Update. September 16, 2022

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. September 15, 2022

Management of renal cell carcinoma in transplant kidney: a systematic review and meta-analysis. September 15, 2022

Screening of Differentially Expressed Iron Death-Related Genes and the Construction of Prognosis Model in Patients with Renal Clear Cell Carcinoma. September 14, 2022

Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study. September 14, 2022

Predicting the probability of malignant pathological type of kidney cancer based on mass size: A retrospective study. September 13, 2022

In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer. September 13, 2022

Correlation between Genes of the ceRNA Network and Tumor-Infiltrating Immune Cells and Their Biomarker Screening in Kidney Renal Clear Cell Carcinoma. September 12, 2022

ImmunoPET Imaging with 89Zr-labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. September 12, 2022

Long-term outcomes of cryoablation for biopsy-proven T1 stage renal cell carcinoma. September 9, 2022

LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration. September 9, 2022

Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma. September 8, 2022

Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis. September 8, 2022

An Evaluation of a Web-Based Decision Aid for Treatment Planning of Small Kidney Tumors: Pilot Randomized Controlled Trial. September 7, 2022

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. September 7, 2022

Digital transformation of perioperative nurse-coordinated protocols in renal surgery for enhanced recovery and outpatient surgery using UroConnect® application. September 6, 2022

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. September 6, 2022

Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus. September 5, 2022

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. September 5, 2022

Artificial intelligence for renal cancer: From imaging to histology and beyond. September 2, 2022

Page 66 of 456